Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-MNC Transfusion in Cerebral Palsy
NCT03826498Phase 2Unknown
- Sponsor
- Samara Regional Medical Center Dinasty
- Start
- Jan 2018
- Primary completion
- Jan 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbilical cord blood mononuclear cells in cerebral palsy (CP) (2 arms), sponsored by Samara Regional Medical Center Dinasty. Primary endpoints: Number of participants with non-serious and serious adverse events at 6 months, Changes in Standardized Gross Motor Function 66 Score at 6 months and 3 more. Status: unknown.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT03826498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826498.